NEWS HIGHLIGHTSMedia Articles Related to Recombivax HB (Hepatitis B Vaccine)
Study Explores Providers' Perceptions Of Parental Concerns About HPV Vaccination
Source: Health News from Medical News Today [2013.05.17]
A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents may be more receptive to vaccinating their daughters against Human Papillomavirus (HPV), while white, middle-class parents are more likely to defer the vaccination. The findings appear online in the May issue of the Journal of Health Care for the Poor and Underserved. Cervical cancer incidence and mortality are markedly higher for low-income and minority women due to higher rates of HPV and limited access to screening and treatment...
HPV Vaccination Sends Genital Wart Cases Plummeting: Study
Source: MedicineNet Cervical Cancer Specialty [2013.04.19]
Title: HPV Vaccination Sends Genital Wart Cases Plummeting: Study
Category: Health News
Created: 4/18/2013 8:35:00 PM
Last Editorial Review: 4/19/2013 12:00:00 AM
Parents Who Veto Vaccinations Often Seek Like-Minded Opinions
Source: MedicineNet Chickenpox (Varicella) Specialty [2013.04.15]
Title: Parents Who Veto Vaccinations Often Seek Like-Minded Opinions
Category: Health News
Created: 4/15/2013 10:35:00 AM
Last Editorial Review: 4/15/2013 12:00:00 AM
Teen's Death From Chickenpox Highlights Need for Vaccination, CDC Reports
Source: MedicineNet Chickenpox (Varicella) Specialty [2013.04.12]
Title: Teen's Death From Chickenpox Highlights Need for Vaccination, CDC Reports
Category: Health News
Created: 4/11/2013 12:35:00 PM
Last Editorial Review: 4/12/2013 12:00:00 AM
We Need A Better Flu Vaccine Before Considering Mandatory Vaccination Of Health Care Workers
Source: Flu / Cold / SARS News From Medical News Today [2013.03.25]
Until we have a better influenza vaccine, it is premature to consider mandatory vaccination for health care workers, states a commentary published in CMAJ (Canadian Medical Association Journal). There has been an increasing push for mandatory vaccination of health care workers in Canada...
Published Studies Related to Recombivax HB (Hepatitis B Vaccine)
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. [2011.07]
BACKGROUND: A modified process hepatitis B vaccine (mpHBV) uses higher phosphate content in the manufacturing process relative to the current product, Recombivax-HB. The higher phosphate is thought to improve antigen presentation, and thereby, increase antibody production. The mpHBV was previously shown to be well tolerated and immunogenic in adults. The current study tested a 2-, 4-, 6-month vaccination schedule and a higher dose formulation (10 mug mpHBV) in healthy infants... CONCLUSIONS: All 4 hepatitis B vaccines elicited high anti-HBs SPRs. After dose 3, anti-HBs GMT were highest in the 10 mug mpHBV group, but did not meet the predefined criteria for superiority. All vaccines were well tolerated.
Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. [2011.06]
BACKGROUND AND AIMS: Assessment of a new, fully liquid, investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi Pasteur), containing the same active ingredients as Pentaxim (DTaP-IPV//PRT-T) and 10 mug Hansenula polymorpha-derived recombinant hepatitis B (Hep B) surface antigen, Sanofi Pasteur, in Argentinean infants... CONCLUSIONS: The new, fully liquid, investigational DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) is highly immunogenic and safe when compared with licensed comparators, warranting further development.
Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients. [2011.05]
OBJECTIVES: The aim of the study was to evaluate the effect of high-flux (HF) hemodialysis (HD) on delayed protective hepatitis B virus (HBV) antibody seroconversion in HD patients who had no response to the classic third dose of HBV vaccination... CONCLUSION: Hemodialysis patients who do not respond to the classic third dose of HBV vaccination could reobtain a delayed higher protective HBV antibody seroconversion rate by HF HD without other intervention.
Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. [2011.05]
BACKGROUND: Prisoners and injecting drug users are at constant risk of hepatitis B virus (HBV) infection and the classic 6-months HBV vaccination might not provide immunization rapidly enough. In this randomized clinical trial we investigated the efficacy of an accelerated vaccination protocol vs. classic schedule among prisoners in Iran... CONCLUSION: Compared to classic HBV vaccination regimen, an accelerated 0, 1, 4 and 8 weeks vaccination schedule can achieve early seroprotection more rapidly, provides clinically sufficient seroprotection with higher compliance in prisoners and can be suggested in situations that rapid immunization against HBV infection is warranted. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. [2011.04.13]
CONTEXT: Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection. OBJECTIVE: To compare the safety and immunogenicity of 4 intramuscular double-dose and 4 intradermal low-dose regimens vs the standard hepatitis B vaccine regimen... CONCLUSION: In adults with HIV-1, both the 4 intramuscular double-dose regimen and the 4 intradermal low-dose regimen improved serological response compared with the standard HBV vaccine regimen. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00480792.
Clinical Trials Related to Recombivax HB (Hepatitis B Vaccine)
Effectiveness of Two Hepatitis B Vaccines in HIV-Negative Youths [Active, not recruiting]
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a
two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate
immunogenicity of the products in this population, barriers to vaccine delivery, and factors
which predict a diminished immune response. Since these youths are also potential candidates
for future HIV vaccine trials, this study will also include preliminary assessment of youths'
understanding of informed consent forms, and willingness to participate in a vaccine trial
and return for multiple visits (including blood draws for immunologic assessment).
Immunologic Memory (Supp. of ATN 024) [Completed]
This is an exploratory, laboratory-based evaluation of cellular immune response to
immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents.
This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune
response in responders and nonresponders to immunization and also evaluate the relationship
of these factors to the persistence of known correlates of serologic protection for the
hepatitis B virus.
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) [Not yet recruiting]
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX-II
compared with the 1XP HEPTAVAX-II in healthy Japanese young adults.
|
